Abstract
Purpose
To identify the efficacy of spectacle wearing for 4 months before amblyopia treatment in children with anisometropic amblyopia.
Methods
The patients with anisometropic amblyopia without strabismus were selected for the present study. The patients were divided into 2 groups; patients who began amblyopia treatment while simultaneously wearing glasses (Group A, 16 patients) and patients who began amblyopia treatment after wearing spectacles for 4 months (Group B, 17 patients). Intermittent atropine penalization or part-time occlusion was provided for amblyopia treatment. Age and best-corrected visual acuity at the start and cessation of treatment, type of amblyopia, treatment method and duration of treatment were analyzed.
Results
There were no statistical differences among age, best-corrected visual acuity of the amblyopic and better eyes, type of amblyopia, or treatment method between the 2 groups. In Group B, visual acuity of the amblyopic and better eyes improved after 4 months of spectacle wearing. At the last visit, there were no statistical differences of visual acuity in the amblyopic eye between the 2 groups. In children with resolution of amblyopia, the treatment duration of Group A (15 patients) was 17.3 months, longer than the 4.7 months in Group B (13 patients) (p = 0.003).
References
1. Pediatric Eye Disease Investigator Group. Treatment of anisom-tropic amblyopia in children with refractive correction. Ophthalmology. 2006; 113:895–903.
2. Kivlin JD, Flynn JT. Therapy of anisometropic amblyopia. J Pediatr Ophthalmol Strabismus. 1981; 18:47–56.
3. Clarke WN, Noel LP. Prognostic indicators for avoiding occlusion therapy in anisometropic amblyopia. Am Orthopt J. 1990; 40:57–63.
4. Moseley MJ, Fielder AR, Irwin M, et al. Effectiveness of occlusion therapy in ametropic amblyopia: a pilot study. Br J Ophthalmol. 1997; 81:956–61.
5. Krumholtz I, FitzGerald D. Efficacy of treatment modalities in refractive amblyopia. J Am Optom Assoc. 1999; 70:399–404.
6. Stewart CE, Moseley MJ, Fielder AR, et al. Refractive adaptation in amblyopia: quantification of effect and implications for practice. Br J Ophthalmol. 2004; 88:1552–6.
7. Moseley MJ, Neufeld M, McCarry B, et al. Remediation of refractive amblyopia by optical correction alone. Ophthalmic Physiol Opt. 2002; 22:296–9.
8. Kim JB, Moon CS, Chang YH, et al. The amblyopia and strabismus accompanied with anisometropia. J Korean Ophthalmol Soc. 2007; 48:411–7.
9. Rho SS, Yang HS, Chang YH, et al. The effect on outcome of amblyopia treatment in children with anisometropic amblyopia. J Korean Ophthalmol Soc. 2007; 48:535–40.
10. Chen PL, Chen JT, Tai MC, et al. Anisometropic amblyopia treated with spectacle correction alone: possible factors predicting success and time to start patching. Am J Ophthalmol. 2007; 143:54–60.
11. Li CH, Chen PL, Chen JT, Fu JJ. Different corrections of hypermetropic errors in the successful treatment of hypermetropic amblyopia in children 3 to 7 years of age. Am J Ophthalmol. 2009; 147:357–63.
12. Kim EK, Choi MY, Kim YH. Clinical analysis of successfully treated amblyopia with anisometropia, strabismis, and combined cause. J Korean Ophthalmol Soc. 2008; 49:303–8.
13. Lee CS, Shin MK, Paik HJ. Evaluation of factors affecting the outcome of occlusion treatment for amblyopia. J Korean Ophthalmol Soc. 2001; 42:1740–6.
14. Kim YT, Chang HR. Follow-up results of the monocular amblyopia. J Korean Ophthalmol Soc. 1998; 39:2803–9.
15. Chang HR, Hong SH, Huh DW. The clinical outcomes of occlusion for monocular amblyopia in children more than 8 years. J Korean Ophthalmol Soc. 2003; 44:1146–52.
16. Park SB, Kwon JY. Occlusion effects on anisometropic amblyopia. J Korean Ophthalmol Soc. 2001; 42:1753–9.
Table 1.
Group A (n = 16) | Group B (n = 17) | p-value | |
---|---|---|---|
Gender (n [%]) | 0.579* | ||
Male | 10 (62.5) | 9 (52.9) | |
Female | 6 (37.5) | 8 (42.1) | |
Age (mean ± SD, yr) | 6.0 ± 1.4 | 6.2 ± 1.3 | 0.773† |
Type of anisometropia (n [%]) | 0.169* | ||
Hyperopia | 12 (75.0) | 8 (47.1) | |
Myopia | 2 (12.5) | 2 (11.8) | |
Astigmatism | 2 (12.5) | 7 (41.1) | |
Initial visual acuity (mean ± SD, logMAR) | |||
Amblyopic eye | 0.72 ± 0.22 | 0.68 ± 0.19 | 0.634† |
Better eye | 0.15 ± 0.17 | 0.22 ± 0.20 | 0.366† |
No. of lines of Interocular acuity difference (mean ± SD) | 5.68 ± 2.02 | 4.64 ± 2.28 | 0.124† |
Interocular difference of spherical equivalent (mean ± SD, diopter) | 3.31 ± 1.62 | 2.76 ± 2.14 | 0.418† |
Absolute value of spherical equivalent of amblyopic eye (mean ± SD, diopter) | 3.98 ± 1.76 | 3.64 ± 1.57 | 0.870† |
Compliance (%) | 99.4 | 96.8 | 0.004† |
Therapeutic methods (n [%]) | 0.622* | ||
Patching | 10 (62.5) | 12 (70.5) | |
Atropine | 6 (37.5) | 5 (29.5) |
Table 2.
Table 3.
Table 4.
Visual acuity (mean ± SD, logMAR) |
p-value* |
||||
---|---|---|---|---|---|
Baseline | 4 mon | Last | 4 mon† | Last‡ | |
Group A (n = 16) | |||||
Amblyopic eye | 0.72 ± 0.22 | 0.35 ± 0.27 | 0.05 ± 0.10 | 0.001 | 0.002 |
Better eye | 0.15 ± 0.17 | 0.08 ± 0.15 | 0.03 ± 0.07 | 0.034 | 0.236 |
Group B (n = 17) | |||||
Amblyopic eye | 0.68 ± 0.19 | 0.57 ± 0.18 | 0.12 ± 0.19 | 0.017 | 0.001 |
Better eye | 0.22 ± 0.20 | 0.07 ± 0.10 | 0.06 ± 0.08 | 0.002 | 0.564 |
Table 5.
Visual acuity (mean ± SD, logMAR) |
p-value* | ||
---|---|---|---|
Group A (n = 16) | Group B (n = 17) | ||
Amblyopic eye | 0.72 ± 0.22 | 0.57 ± 0.18 | 0.074 |
Better eye | 0.15 ± 0.17 | 0.07 ± 0.10 | 0.160 |